Evozyne

Evozyne is a company dedicated to creating novel protein systems that contribute to a healthier world. In September 2023, Evozyne announced an $81 million financing round to advance its use of generative AI for therapeutic discovery and drug development. The company collaborates with NVIDIA to develop AI models for novel protein design, which are expected to significantly accelerate drug development processes. Additionally, Evozyne has engaged in a multi-target research collaboration and license agreement with Takeda to develop next-generation gene therapies, focusing on innovative protein engineering technology to address treatment challenges in rare diseases. Evozyne’s products include high-performance, adaptive proteins with advanced functionality aimed at life-changing treatments and potential cures for previously untreatable diseases. The company’s technology approach involves evolutionary design directed by generative AI to create novel high-performance proteins that function to specification.